Document:

exv10w19

 

Exhibit 10.19

iPass Inc.

Management Bonus Structure

2005 Plan

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	Lower	 	 	Target	 	 	Upper	 
	2005 Financial Incentive Goals	 	Weight	 	 	Boundary	 	 	Plan	 	 	Boundary	 
	 
	Broadband and New Services Revenues
	 	 	[*]	%	 	$	[*]	 	 	$	[*]	 	 	$	[*]	 
	Total iPass Revenues
	 	 	[*]	%	 	$	[*]	 	 	$	[*]	 	 	$	[*]	 
	Non-GAAP Earnings Per Share
	 	 	[*]	%	 	$	[*]	 	 	$	[*]	 	 	$	[*]	 
	Contract MC
	 	 	[*]	%	 	$	[*]	 	 	$	[*]	 	 	$	[*]	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	100.0	%	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 

	 
	2005 Participant Payout Schedule:

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Officer	 	Officer	 	Annual	 	 	Quarterly	 	 	Quarterly	 	 	Q1	 	 	Incentive	 
	Name	 	Title	 	Incentive	 	 	Incentive	 	 	Incentive @ 80%	 	 	Payout	 	 	Variance	 
	 
	Denman*
	 	Kenneth D.	 	Chairman and CEO	 	$	150,000	 	 	$	37,500	 	 	$	37,500	 	 	 	 	 	 	 	 	 
	Charters
	 	John	 	Chief Operating Officer	 	$	100,000	 	 	$	25,000	 	 	$	20,000	 	 	 	 	 	 	 	 	 
	Lal
	 	Anurag	 	VP, Business Development	 	$	100,000	 	 	$	25,000	 	 	$	20,000	 	 	 	 	 	 	 	 	 
	McCauley
	 	Donald C.	 	VP, Fin. & Admin. and CFO	 	$	100,000	 	 	$	25,000	 	 	$	20,000	 	 	 	 	 	 	 	 	 
	Posey
	 	Bruce K.	 	VP, Gen. Counsel and Corp. Sec.	 	$	80,000	 	 	$	20,000	 	 	$	16,000	 	 	 	 	 	 	 	 	 
	Thuma
	 	John P.	 	VP, Worldwide Sales	 	$	100,000	 	 	$	25,000	 	 	$	20,000	 	 	 	 	 	 	 	 	 
	Wachtler
	 	Joel B.	 	VP, Prod. Mgmt. and Strategy	 	$	65,000	 	 	$	16,250	 	 	$	13,000	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	$	146,500	 	 	$	—	 	 	$	—	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 

2005 Methodology:

100% paid at Target level, 50% at Lower Boundary, 150% at Upper Boundary;

Straight line pro-rata calculation between levels;

Below Lower Boundary, no payment. Above Upper Boundary, straight-line additional payout;

Separate Targets set for each quarter (see attached); each quarter stands on its own.

* Mr. Denman has 100% of quarterly incentive tied to this management bonus plan. All others have 80% tied to this plan and 20% personal objectives.

[*] Indicates target levels with respect to specific quantitative or qualitative performance related-factors,
or factors or criteria involving confidential commercial or business information, the disclosure of
which would have an adverse effect on iPass Inc., which have not been provided consistent with the treatment of similar
information under Instruction 2 to Item 402(k) of Regulation S-K.

 

 

MANAGEMENT BONUS PROGRAM
2005

Financial Targets

	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	50%	 	 	100%	 	 	150%	 
	 	 	Lower	 	 	Company	 	 	Upper	 
	 	 	Boundary	 	 	Target	 	 	Boundary	 
	1st Quarter 2005
	 	 	 	 	 	 	 	 	 	 	 	 
	Total iPass Revenues
	 	 	[*]	 	 	 	[*]	 	 	 	[*]	 
	Non-GAAP EPS
	 	$	[*]	 	 	$	[*]	 	 	$	[*]	 
	Contract MC
	 	 	[*]	 	 	 	[*]	 	 	 	[*]	 
	Broadband & New Services Revenue
	 	 	[*]	 	 	 	[*]	 	 	 	[*]	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	2nd Quarter 2005
	 	 	 	 	 	 	 	 	 	 	 	 
	Total iPass Revenues
	 	 	[*]	 	 	 	[*]	 	 	 	[*]	 
	Non-GAAP EPS
	 	$	[*]	 	 	$	[*]	 	 	$	[*]	 
	Contract MC
	 	 	[*]	 	 	 	[*]	 	 	 	[*]	 
	Broadband & New Services Revenue
	 	 	[*]	 	 	 	[*]	 	 	 	[*]	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	3rd Quarter 2005
	 	 	 	 	 	 	 	 	 	 	 	 
	Total iPass Revenues
	 	 	[*]	 	 	 	[*]	 	 	 	[*]	 
	Non-GAAP EPS
	 	$	[*]	 	 	$	[*]	 	 	$	[*]	 
	Contract MC
	 	 	[*]	 	 	 	[*]	 	 	 	[*]	 
	Broadband & New Services Revenue
	 	 	[*]	 	 	 	[*]	 	 	 	[*]	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	4th Quarter 2005
	 	 	 	 	 	 	 	 	 	 	 	 
	Total iPass Revenues
	 	 	[*]	 	 	 	[*]	 	 	 	[*]	 
	Non-GAAP EPS
	 	$	[*]	 	 	$	[*]	 	 	$	[*]	 
	Contract MC
	 	 	[*]	 	 	 	[*]	 	 	 	[*]	 
	Broadband & New Services Revenue
	 	 	[*]	 	 	 	[*]	 	 	 	[*]	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	Full Year 2005
	 	 	 	 	 	 	 	 	 	 	 	 
	Total iPass Revenues
	 	 	[*]	 	 	 	[*]	 	 	 	[*]	 
	Non-GAAP EPS
	 	 	[*]	 	 	 	[*]	 	 	 	[*]	 
	Contract MC
	 	 	[*]	 	 	 	[*]	 	 	 	[*]	 
	Broadband & New Services Revenue
	 	 	[*]	 	 	 	[*]	 	 	 	[*]	 

Notes

Broadband revenues for the Lower and Upper Boundaries are based on a –[*]% and +[*]% adjustment to the target revenue.
Revenues for the Lower and Upper Boundaries are based on a -[*]% and +[*]% adjustment to the target revenue

Non-GAAP EPS for the Lower and Upper Boundaries are based on a -$[*] and +$[*] adjustment, except for Q1 & Q2 where Lower Boundary set
Contract MC for the Lower Boundary is based on quarterly average 2004 MC results and the Upper Boundary is based on Sales quota targets

New Services Revenue for the Lower and Upper Boundaries are based on a -[*]% and +[*]% adjustment from the Target.

[*] Indicates target levels with respect to specific quantitative or qualitative performance related-factors,
or factors or criteria involving confidential commercial or business information, the disclosure of
which would have an adverse effect on iPass Inc., which have not been provided consistent with the treatment of similar
information under Instruction 2 to Item 402(k) of Regulation S-K.exv4w1

 

Exhibit 4.1

STOCK PURCHASE AGREEMENT

BioCryst Pharmaceuticals, Inc.

2190 Parkway Lake Drive

Birmingham, AL 35244

The undersigned investors (each an “Investor” and collectively the “Investors”), hereby confirm
their agreement with you as follows:

1.       This Stock Purchase Agreement (the “Agreement”) is made as of the date set forth below between
BioCryst Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and the Investors listed on
Exhibit A.

2.       The Company has authorized the sale and issuance of up to 4,350,000 shares (the “Shares”) of
common stock of the Company, $0.01 par value per share (the “Common Stock”), subject to adjustment
by the Company’s Board of Directors, to certain investors in a registered direct offering (the
“Offering”).

3.       The Company and the Investors, severally and not jointly, agree that the Investors will purchase
from the Company and the Company will issue and sell to the Investors an aggregate of 1,454,545
shares, for a purchase price of $5.50 per share, or an aggregate purchase price of $8,000,000,
pursuant to the Terms and Conditions for Purchase of Shares attached hereto as Annex I and
incorporated herein by this reference as if fully set forth herein. Unless otherwise requested by
the Investors, certificates representing the Shares purchased by the Investors will be registered
in each Investor’s name and address as set forth below.

4.       Each Investor represents that, except as set forth below, (a) it has had no position, office or
other material relationship within the past three years with the Company or its affiliates, (b)
neither it, nor any group of which it is a member or to which it is related, beneficially owns
(including the right to acquire or vote) any securities of the Company and (c) it has no direct or
indirect affiliation or association with any NASD member. Exceptions:

(If no exceptions, write “none.” If left blank, response will be deemed to be “none.”)

 

 

Please confirm that the foregoing correctly sets forth the agreement between us by signing in the
space provided below for that purpose.

	 	 	 
	

	 	Dated as of: February 17, 2005
(the “Execution Date”)
	 
	 	 
	“INVESTOR”

	 	“INVESTOR”
	Baker Bros. Investments, L.P.

	 	Baker Biotech Fund II, L.P.
	By: Baker Bros. Capital, L.P., (general partner)

	 	By: Baker Biotech Capital II, L.P., (general partner)
	By: Baker Bros. Capital (GP), LLC, (general partner)

	 	By: Baker Biotech Capital II (GP), LLC, (general partner)
	By: Julian Baker, Managing Member

	 	By: Julian Baker, Managing Member
	 
	 	 
	/s/ Julian Baker

	 	/s/ Julian Baker
	 

	 	 
	 
	 	 
	 
	 	 
	“INVESTOR”

	 	“INVESTOR”
	Baker Bros. Investments II, L.P.

	 	Baker Biotech Fund II (Z), L.P.
	By: Baker Bros. Capital, L.P., (general partner)

	 	By: Baker Biotech Capital II (Z), L.P., (general partner)
	By: Baker Bros. Capital (GP), LLC, (general partner)

	 	By: Baker Biotech Capital II (Z) (GP), LLC, (general partner)
	By: Julian Baker, Managing Member

	 	By: Julian Baker, Managing Member
	 
	 	 
	/s/ Julian Baker

	 	/s/ Julian Baker
	 

	 	 
	 
	 	 
	 
	 	 
	“INVESTOR”

	 	“INVESTOR”
	Baker/Tisch Investments, L.P.

	 	Baker Biotech Fund III, L.P.
	By: Baker/Tisch Capital, L.P., (general partner)

	 	By: Baker Biotech Capital III, L.P., (general partner)
	By: Baker/Tisch Capital (GP), LLC, (general partner)

	 	By: Baker Biotech Capital III (GP), LLC, (general partner)
	By: Julian Baker, Managing Member

	 	By: Julian Baker, Managing Member
	 
	 	 
	/s/ Julian Baker

	 	/s/ Julian Baker
	 

	 	 
	 
	 	 
	 
	 	 
	“INVESTOR”

	 	“INVESTOR”
	Baker Biotech Fund I, L.P.

	 	Baker Biotech Fund III (Z), L.P.
	By: Baker Biotech Capital, L.P., (general partner)

	 	By: Baker Biotech Capital III (Z), L.P., (general partner)
	By: Baker Biotech Capital (GP), LLC, (general partner)

	 	By: Baker Biotech Capital III (Z) (GP), LLC, (general partner)
	By: Julian Baker, Managing Member

	 	By: Julian Baker, Managing Member
	 
	 	 
	/s/ Julian Baker

	 	/s/ Julian Baker
	 

	 	 
	 
	 	 
	 
	 	 
	

	 	“INVESTOR”
	

	 	14159, L.P.
	

	 	By: 14159 Capital, L.P., (general partner)
	

	 	By: 14159 Capital (GP), LLC, (general partner)
	

	 	By: Julian Baker, Managing Member
	 
	 	 
	 

	 	/s/ Julian Baker
	

	 	 

	 	 	 	 	 	 	 
	AGREED AND ACCEPTED:
BIOCRYST PHARMACEUTICALS, INC.	 	 
	 
	 	 	 	 	 	 
	By:
	 	/s/ Michael A. Darwin	 	 	 	 
	

	 	 	 	 	 	 
	Title:
	 	Chief Financial Officer	 	 	 	 
	

	 	 	 	 	 	 

 

 

ANNEX I

TERMS AND CONDITIONS FOR PURCHASE OF SHARES

1.       Authorization and Sale of the Shares; Registration. Subject to the terms and conditions of
this Agreement, the Company has authorized the sale of the Shares. The Shares have been registered
on a Form S-3, File No. 333-111226 (the “Registration Statement”), which registration statement has
been declared effective by the Securities and Exchange Commission (the “Commission”) on January 5,
2004, has remained effective since such date and is effective on the date hereof.

2.       Agreement to Sell and Purchase the Shares; Subscription Date; Additional Agreements.

2.1       At the Closing (as defined in Section 3), the Company will sell to the Investors, and the
Investors, severally and not jointly, will purchase from the Company, upon the terms and conditions
hereinafter set forth, the respective number of Shares set forth opposite each Investor’s name on
Exhibit A hereto at the purchase price set forth on such Exhibit A.

2.2       The Company may enter into this same or a similar form of Stock Purchase Agreement with
certain other investors (the “Other Investors”) and may complete sales of Shares to them. (The
Investors and the Other Investors are hereinafter sometimes collectively referred to as the
“Investors,” and this Agreement and the Stock Purchase Agreements executed by the Other Investors
are hereinafter sometimes collectively referred to as the “Agreements.”)

2.3       The Investors acknowledge that: (a) the Company has retained Leerink Swann & Company as
placement agent (in its capacity as placement agent of the Shares, the “Placement Agent”); (b) the
Company intends to pay the Placement Agent a fee in respect of the sale of Shares to the Investors;
and (c) the offering of the Shares is not a firm commitment underwriting.

2.4       (a)    The Investors will have the right to appoint a member to the Company’s Board of
Directors as of the Closing Date (“Investor Director”),
which right shall be valid for a period of 12 months from the
Closing Date. So long as the Investors in the aggregate
continue to own not less than 1,150,000 shares of Common Stock (appropriately adjusted for stock
splits, reverse stock splits, stock dividends and the like), and
exercise their right within the 12 month period from the Closing
Date, the Investor Director shall have a
right to serve on the Board of Directors, subject to the same terms
and conditions as the Company’s other Directors. The Investor
Director may resign from the Board of Directors at any time without
notice and may
not be removed from the Board of Directors by the Company without “Cause” as defined in subsection
(b) below.

      (b)    For purposes of this Section 2.4, the following shall constitute “Cause”: (i) any action
by the Investor Director constituting fraud or embezzlement in the course of his tenure on the
Board of Directors, (ii) any conviction of the Investor Director of a felony which would materially
and adversely interfere with the Investor Director’s ability to perform his or her duties as a
member of the Board of Directors; (iii) continued gross neglect or willful refusal by the Investor
Director to perform his or her duties hereunder for a period of ten (10) days following notice to
the Investor Director of such inaction; or (iv) a material breach by the Investor Director of any
other material obligations under this Agreement or the Company’s By-

1

 

laws if such breach is not curable or, if curable, is not cured within thirty (30) days after
written notice thereof by the Company to the Investor Director.

3.       Delivery of the Shares at Closing. The completion of the purchase and sale of the Shares
(the “Closing”) shall occur at the offices of Holme Roberts & Owen LLP, 1700 Lincoln Street, Suite
4100, Denver, Colorado 80203, at 10:00 o’clock A.M. E.S.T. on February 18, 2005 (the “Closing
Date”), but in no event earlier than such date and time as American Stock Transfer & Trust Company,
as escrow agent (the “Escrow Agent”) shall have received all of the executed Stock Purchase
Agreements. The executed Stock Purchase Agreements and the purchase price transferred by the
Investor (jointly the “Escrowed Property”) will be held by the Escrow Agent until the Closing is
confirmed by the Company and Placement Agent, under the terms and conditions set forth in the
Escrow Agreement to be entered into on the Closing Date by and among the Company, the Placement
Agent and the Escrow Agent substantially in the form attached hereto as Exhibit B (the “Escrow
Agreement”). If the Closing does not occur, the funds will be returned to the Investor. All wires
should be sent to the Escrow Agent, JP Morgan Chase, 55 Water Street, New York, NY 10041, ABA# 021
000 021, Account #323 213251, Attention: Henry Reinhold. At the Closing, upon written instruction
of the Company and the Placement Agent, the Escrow Agent shall release the Escrowed Property (in
accordance with the provisions of the Escrow Agreement) to the Company and the Company shall
arrange delivery to the Investor one or more stock certificates representing the number of Shares
set forth on the Signature Page hereto, each such certificate to be registered in the name of the
Investor or, if so indicated on the Stock Certificate Questionnaire attached hereto as Exhibit
A, in the name of a nominee designated by the Investor. Such stock certificates shall be
unlegended and free of any resale restrictions.

The Company’s obligation to issue the Shares to the Investors shall be subject to the
following conditions, any one or more of which may be waived by the Company: (a) receipt by the
Company of the purchase price for the Shares being purchased hereunder as set forth on Exhibit
A hereto; and (b) the accuracy of the representations and warranties made by the Investors and
the fulfillment of those undertakings of the Investors to be fulfilled prior to the Closing.

Each Investor’s obligation to purchase the Shares shall be subject to the following
conditions, any one or more of which may be waived by the Investor: (a) trading in the Common Stock
shall not have been suspended by the Commission (except for any suspension of trading of limited
duration agreed to by the Company, which suspension shall be terminated prior to the Closing Date);
(b) no stop order suspending the effectively of the Registration Statement shall have been issued
and no proceedings for that purpose shall have been initiated or threatened by the Commission; and
(c) receipt of a satisfactory legal opinion from the Company’s legal counsel pursuant to Section
2.5 of this Agreement. The Investor’s obligations are expressly not conditioned on the purchase by
any or all of the other Investors, if any, of the Shares that they have agreed to purchase from the
Company.

4.       Representations, Warranties and Covenants of the Company. Except as otherwise described in
the Registration Statement and the Company’s filings with the Commission since December 31, 2003
(the “Commission Documents”), in the Company’s press releases since December 31, 2003, and in the
certain operational, managerial and other

2

 

information regarding the Company (the “Proprietary Information”) disclosed by the Company to
the Investors in contemplation of this offering, including the documents incorporated by reference
therein (the Commission Documents, press releases and the Proprietary Information are collectively
referred to herein as the “Company Information”), which qualify the following representations and
warranties in their entirety, the Company hereby represents and warrants to, and covenants with,
the Investors, as follows:

4.1       Organization, Good Standing and Qualification. The Company is a corporation duly
organized, validly existing and in good standing under the laws of the State of Delaware and has
full corporate power and lawful authority to conduct its business as described in its Company
Information. The Company is duly qualified to do business as a foreign corporation and is in good
standing in each jurisdiction in which the nature of the business conducted or as proposed to be
conducted in its Company Information, by it or the properties owned, leased or operated by it,
makes such qualification or licensing necessary and where the failure to be so qualified or
licensed would have a material adverse effect upon the business, properties or financial condition
of the Company (“Material Adverse Effect”).

4.2       Capitalization and Voting Rights. The authorized, issued and outstanding capital stock of
the Company is as set forth in its Commission Documents as of the date thereof; all issued and
outstanding shares of capital stock of the Company are validly issued, fully paid and
nonassessable. Except as set forth in the Company Information and except for shares reserved for
issuance pursuant to employee and consultant benefit and option plans within the limits specified
therein, there are no outstanding options, warrants, agreements, commitments, convertible
securities, preemptive rights or other rights to subscribe for or to purchase any shares of capital
stock of the Company nor are there any agreements, promises or commitments to issue any of the
foregoing. Except as set forth in the Company’s SEC filings, in this Agreement and as otherwise
required by law, there are no restrictions upon the voting or transfer of the Shares pursuant to
the Company’s Certificate of Incorporation, as amended, (the “Certificate of Incorporation”),
By-laws or other governing documents or any agreement or other instruments to which the Company is
a party or by which the Company is bound.

4.3       Authorization; Enforceability. The Company has all corporate right, power and authority to
enter into this Agreement and to consummate the transactions contemplated hereby. All corporate
action on the part of the Company, its directors and stockholders necessary for the authorization,
execution, delivery and performance of this Agreement by the Company, the authorization, sale,
issuance and delivery of the Shares and the performance of the Company’s obligations hereunder has
been taken. This Agreement has been duly executed and delivered by the Company and constitutes a
legal, valid and binding obligation of the Company, enforceable against the Company in accordance
with its terms, subject to laws of general application relating to bankruptcy, insolvency and the
relief of debtors and rules of law governing specific performance, injunctive relief or other
equitable remedies, and to limitations of public policy. The Shares have been duly and validly
authorized and, upon the issuance and delivery thereof and payment therefor as contemplated by
this Agreement, will be free and clear of liens other than liens caused by the Investors, duly and
validly authorized and issued, fully paid and nonassessable. The issuance and sale of the Shares
contemplated hereby will not give rise to any preemptive rights or rights of first refusal on
behalf of any person.

3

 

4.4       No Conflict; Governmental Consents.

     (a)    The execution and delivery by the Company of this Agreement, the consummation of the
transactions contemplated hereby and the offer and sale of the Shares will not result in the
violation of any material law, statute, rule, regulation, order, writ, injunction, judgment or
decree of any court or governmental authority to or by which the Company is bound, or of any
provision of the Certificate of Incorporation or By-laws of the Company, and will not conflict
with, or result in a breach or violation of, any of the terms or provisions of, or constitute (with
due notice or lapse of time or both) a default under, any lease, loan agreement, mortgage, security
agreement, trust indenture or other agreement or instrument to which the Company is a party or by
which it is bound or to which any of its properties or assets is subject, where such conflict,
breach or default is likely to result in a Material Adverse Effect, nor result in the creation or
imposition of any lien upon any of the material properties or assets of the Company.

      (b)    No consent, waiver, approval, authorization or other order of any governmental authority
is required to be obtained by the Company in connection with the authorization, execution and
delivery of this Agreement or with the authorization, issuance and sale of the Shares, except such
filings as may be required to be made, and which shall have been made at or prior to the required
time, with the SEC, the NASD and The Nasdaq Stock Market, Inc. (“Nasdaq”), and with any state or
foreign blue sky or securities regulatory authority.

4.5       Licenses. The Company has all licenses, permits and other governmental authorizations
currently required for the conduct of its business or ownership of properties and is in all
material respects complying therewith, except for any licenses, permits or other governmental
authorizations, the lack of which would not likely result in a Material Adverse Effect.

4.6       Litigation. The Company knows of no pending or threatened legal or governmental
proceedings against the Company which would likely result in a Material Adverse Effect.

4.7       Accuracy of Reports. All reports required to be filed by the Company within the three
years prior to the date of this Agreement under the Securities Exchange Act of 1934, as amended,
(the “Exchange Act”), have been duly and timely filed with the SEC, complied at the time of filing
in all material respects with the requirements of their respective forms and, were complete and
correct in all material respects as of the dates at which the information was furnished, and
contained (as of such dates) no untrue statement of a material fact or omitted to state a material
fact necessary in order to make the statements contained therein, in light of the circumstances
under which they were made, not misleading.

4.8       Investment Company. The Company is not an “investment company” within the meaning of such
term under the Investment Company Act of 1940, as amended, and the rules and regulations of the
SEC thereunder.

4.9       Listing. The Company has filed a Notification Form: Listing of Additional Shares with the
Nasdaq Stock Market and hereby represents and warrants to the

4

 

Placement Agent and the Investors that it will take any other necessary action in accordance
with the rules of the Nasdaq Stock Market to enable the Shares to trade on the Nasdaq Stock Market.

4.10       No Material Adverse Change. Except as disclosed in the Company Information, since the
filing of the Company’s most recent Quarterly Report on Form 10-Q, (i) there has not been any
Material Adverse Effect, and (ii) there has been no event or condition of any character that would
likely result in a Material Adverse Effect.

4.11       Financial Statements. The financial statements included in the Company’s most recent
Annual Report on Form 10-K, for the fiscal year ended December 31, 2003, and all other reports
filed by the Company pursuant to the Exchange Act since the filing of such Annual Report on Form
10-K and prior to the date hereof (collectively, the “SEC Filings”) present fairly and accurately
in all material respects the financial position of the Company as of the dates shown and its
results of operations and cash flows for the periods shown, and such financial statements have been
prepared in conformity with generally accepted accounting principles applied on a consistent basis.
Except as set forth in the financial statements of the Company included in the SEC Filings filed
prior to the date hereof, to the best of the Company’s knowledge, the Company has no liabilities,
contingent or otherwise, except those which individually or in the aggregate are not material to
the financial condition or operating results of the Company.

4.12       Compliance with Laws. The Company is in compliance with all applicable Nasdaq continued
listing requirements. There are no proceedings pending or to the Company’s knowledge threatened
against the Company relating to the continued listing of the Company’s Common Stock on the Nasdaq
Stock Market and the Company has not received any notice of, nor to the knowledge of the Company is
there any basis for, the delisting of the Common Stock from the Nasdaq Stock Market.

4.13       Sarbanes-Oxley Act. The Company is in substantial compliance with the applicable
provisions of the Sarbanes-Oxley Act of 2002 (the “Sarbanes-Oxley Act”), and the rules and
regulations promulgated thereunder, that are effective and intends to comply substantially with
other applicable provisions of the Sarbanes-Oxley Act, and the rules and regulations promulgated
thereunder, upon the effectiveness of such provisions.

4.14       Disclosure. To the best of the Company’s knowledge, neither this Agreement nor any other
documents, certificates or instruments furnished to the Investors by or on behalf of the Company or
any Subsidiary in connection with the transactions contemplated by this Agreement, taken as a whole
together with the Company Information, contain any untrue statement of a material fact or omit to
state a material fact necessary in order to make the statements made herein or therein, in the
light of the circumstances under which they were made herein or therein, not misleading.

4.15       Registration Statement; Effectiveness. The sale and issuance by the Company of the
Shares have been validly registered pursuant to the Registration Statement and such Shares of
Common Stock will be issued without a restrictive legend.

5

 

5.       Representations, Warranties and Covenants of the Investors.

5.1       Each Investor individually represents and warrants to, and covenants with, the Company
that: (i) the Investor is knowledgeable, sophisticated and experienced in making, and is qualified
to make decisions with respect to, investments in shares presenting an investment decision like
that involved in the purchase of the Shares, including investments in Shares issued by the Company
and investments in comparable companies, and has requested, received, reviewed and considered all
information it deemed relevant in making an informed decision to purchase the Shares; (ii) the
Investor is acquiring the number of Shares set forth on Exhibit A hereto in the ordinary
course of its business and for its own account for investment only and with no present intention of
distributing any of such Shares or any arrangement or understanding with any other persons
regarding the distribution of such Shares in violation of the securities laws (this representation
and warranty not limiting such Investor’s right to sell the Shares pursuant to the Registration
Statement or otherwise in compliance with applicable federal and state securities laws); (iii) the
Investor will not, directly or indirectly, offer, sell, pledge, transfer or otherwise dispose of
(or solicit any offers to buy, purchase or otherwise acquire or take a pledge of) any of the Shares
except in compliance with the Securities Act, applicable state securities laws and the respective
rules and regulations promulgated thereunder; and (iv) the Investor, after giving effect to the
transactions contemplated hereby, will not, either individually or with a group (as defined in
Section 13(d)(3) of the Exchange Act), be the beneficial owner of 15% or more of the Company’s
outstanding Common Stock. For purposes of this Section 5.1, beneficial ownership shall be
determined pursuant to Rule 13d-3 under the Exchange Act.

5.2       Each Investor individually acknowledges, represents and agrees that no action has been or
will be taken in any jurisdiction outside the United States by the Company or the Placement Agent
that would permit an offering of the Shares, or possession or distribution of offering materials in
connection with the issue of the Shares, in any jurisdiction outside the United States where action
for that purpose is required. Each Investor outside the United States will comply with all
applicable laws and regulations in each foreign jurisdiction in which it purchases, offers, sells
or delivers Shares or has in its possession or distributes any offering material, in all cases at
its own expense. The Placement Agent is not authorized to make any representation or use any
information in connection with the issue, placement, purchase and sale of the Shares.

5.3       Each Investor hereby covenants with the Company not to make any sale of the Shares without
effectively causing the prospectus delivery requirement under the Securities Act to be satisfied.
Each Investor acknowledges that there may occasionally be times when the Company, based on the
advice of its counsel, determines that it must suspend the use of the Prospectus forming a part of
the Registration Statement until such time as an amendment to the Registration Statement has been
filed by the Company and declared effective by the Commission or until the Company has amended or
supplemented such Prospectus.

5.4       Each Investor further represents and warrants to, and covenants with, the Company that (i)
the Investor has full right, power, authority and capacity to enter into this Agreement and to
consummate the transactions contemplated hereby and has taken all necessary action to authorize the
execution, delivery and performance of this Agreement, and (ii) this Agreement constitutes a valid
and binding obligation of the Investor enforceable against the

6

 

Investor in accordance with its terms, except as enforceability may be limited by applicable
bankruptcy, insolvency, reorganization, moratorium or similar laws affecting creditors’ and
contracting parties’ rights generally and except as enforceability may be subject to general
principles of equity (regardless of whether such enforceability is considered in a proceeding in
equity or at law) and except as the indemnification agreements of the Investors herein may be
legally unenforceable.

5.5       Each Investor understands that nothing in this Agreement or any other materials presented
to the Investor in connection with the purchase and sale of the Shares constitutes legal, tax or
investment advice. Each Investor has consulted such legal, tax and investment advisors as it, in
its sole discretion, has deemed necessary or appropriate in connection with its purchase of Shares.

6.       Survival of Representations, Warranties and Agreements. Notwithstanding any investigation
made by any party to this Agreement or by the Placement Agent, all covenants, agreements,
representations and warranties made by the Company and each of the Investors herein shall survive
the execution of this Agreement, the delivery to the Investor of the Shares being purchased and the
payment therefor.

7.       Notices. All notices, requests, consents and other communications hereunder shall be in
writing, shall be mailed (A) if within domestic United States by first-class registered or
certified airmail, or nationally recognized overnight express courier, postage prepaid, or by
facsimile, or (B) if delivered from outside the United States, by International Federal Express or
facsimile, and shall be deemed given (i) if delivered by first-class registered or certified mail
domestic, three business days after so mailed, (ii) if delivered by nationally recognized overnight
carrier, one (1) business day after so mailed, (iii) if delivered by International Federal Express,
two (2) business days after so mailed, (iv) if delivered by facsimile, upon electric confirmation
of receipt and shall be delivered as addressed as follows:

(a)     if to the Company, to:

BioCryst Pharmaceuticals, Inc.

2190 Parkway Lake Drive

Birmingham, AL 35244

Attn: Chief Executive Officer

Phone: (205) 444-4600

Telecopy: (205) 444-4640

7

 

(b)     with a copy mailed to:

Holme Roberts & Owen LLP

1700 Lincoln Street, Suite 4100

Denver, CO 80203

Attn: Richard R. Plumridge, Esq.

Phone: (303) 861-7000

Telecopy: (303) 866-0200

(c)       if to the Investors, at their addresses on the on the signature page to which these Terms
and Conditions for Purchase of Shares are attached as Annex I, or at such other address or
addresses as may have been furnished to the Company in writing.

8.       Changes. This Agreement may not be modified or amended except pursuant to an instrument in
writing signed by the Company and the Investors.

9.       Headings. The headings of the various sections of this Agreement have been inserted for
convenience of reference only and shall not be deemed to be part of this Agreement.

10.       Severability. In case any provision contained in this Agreement should be invalid,
illegal or unenforceable in any respect, the validity, legality and enforceability of the remaining
provisions contained herein shall not in any way be affected or impaired thereby.

11.       Governing Law. This Agreement shall be governed by, and construed in accordance with, the
internal laws of the State of New York, without giving effect to the principles of conflicts of
law.

12.       Counterparts. This Agreement may be executed in two or more counterparts, each of which
shall constitute an original, but all of which, when taken together, shall constitute but one
instrument, and shall become effective when one or more counterparts have been signed by each party
hereto and delivered to the other parties.

13.       Confidential Disclosure Agreement. Notwithstanding any provision of this Agreement to the
contrary, any confidential disclosure agreement previously executed by the Company and the
Investors in connection with the transactions contemplated by this Agreement shall remain in full
force and effect in accordance with its terms following the execution of this Agreement and the
consummation of the transactions contemplated hereby.

14.       Third Party Beneficiary. Except as provided on Exhibit C, nothing in this
Agreement shall create or be deemed to create any rights in any person or entity not a party to
this Agreement.

* * * *

8

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00078-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00078-of-00352.parquet"}]]